B+
Bull case
25%
Probability
Target price
$3.00
+158.6% vs current
PLRX
Pliant TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.70
+46.6% vs current
B-
Bear case
25%
Probability
Target price
$0.45
-61.2% vs current
AI sentiment snapshot
Latest data as of 2026-05-29
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+97.3
Score
AI commentary
Low-coverage monitoring view. The primary-source update is constructive because it improves runway and confirms first FORTIFY dosing, but forward visibility is still limited until the 2027 interim data window. No fresh analyst revisions or target changes were in the packet, the $2.50 median target should be treated as a rough reference rather than strong consensus, and the peer set is loose enough to keep conviction capped. Recent tone is positive, but it is mostly company-driven rather than market-confirmed.
RankAlpha Sentiment Codex - 2026-05-29
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-09-30catalystQ1 2026 update reduced burn and extended runwayMedium impact
The May 11, 2026 SEC release showed R&D fell to $13.6M from $43.4M, G&A fell to $8.2M, net loss narrowed to $20.0M, and cash/cash equivalents plus short-term investments totaled $172.4M, with management expecting funding into the second half of 2028. That lowers near-term dilution pressure and keeps the stock focused on clinical execution. [#8-K-2026-05-11][#10-Q-2026-05-11]
2026-12-31eventFORTIFY enrollment and indication-expansion progressHigh impact
Pliant said the first participant was dosed in FORTIFY in April 2026 and that the Phase 1b trial is enrolling NSCLC, clear cell renal cell carcinoma, and high-tumor-mutational-burden cohorts, with interim data expected in 2027. Continued enrollment and clean safety/tolerability updates would keep PLN-101095 moving toward a broader value inflection. [#8-K-2026-05-11]
2027-12-31catalyst2027 interim data is the real rerating testHigh impact
The Phase 1 update reported one confirmed complete response, two confirmed partial responses, and one unconfirmed partial response in a heavily pretreated population, but the investment case still hinges on whether that signal broadens in the 2027 interim dataset. If the response pattern holds, PLRX can transition from a balance-sheet story to a more credible single-asset oncology optionality story; if not, the stock likely reverts to cash-burn and financing scrutiny. [#8-K-2026-05-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-29 • Updated nightlySource: Internal modelMethodology